Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95.

@article{Park2008MitogenactivatedPK,
  title={Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95.},
  author={Margaret M. Park and Guo Yong Zhang and Christopher A. Mitchell and Mohamed Rahmani and Hossein Akbari Hamed and Michael Philip Hagan and Abraham Yacoub and David T Curiel and Paul B Fisher and Steven Grant and Paul Washington Dent},
  journal={Molecular cancer therapeutics},
  year={2008},
  volume={7 9},
  pages={
          2633-48
        }
}
Prior studies have noted that inhibitors of mitogen-activated protein kinase (MAPK) kinase 1/2 (MEK1/2) enhanced geldanamycin lethality in malignant hematopoietic cells by promoting mitochondrial dysfunction. The present studies focused on defining the mechanism(s) by which these agents altered survival in carcinoma cells. MEK1/2 inhibitors [PD184352; AZD6244 (ARRY-142886)] interacted in a synergistic manner with geldanamycins [17-allylamino-17-demethoxygeldanamycin (17AAG) and 17… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 17 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 49 REFERENCES

Similar Papers

Loading similar papers…